🔗 Share this article

A shadow market for unapproved slimming drugs is propelled by social media fitness personalities and sellers on communication apps, based on recent findings.

Experimental Treatment Acquiring Popularity Via Social Media

The experimental drug, which remains in research studies, is being advertised by online personalities for its supposed weight-reducing properties. Viewers are urged to contact these accounts privately for supplier links, while also obtaining discount codes.

Active Trade on Social Networks

Separately, a robust trade exists on messaging services, where groups with thousands of participants share “before and after” photos, administration instructions and assertions of rapid UK delivery. Vendors promote the drug there before redirecting customers to other platforms for transactions.

Learning About The Experimental Drug

Retatrutide is an investigational injection developed by US drugmaker Eli Lilly. The treatment targets three gut hormones – glucagon-like peptide-1, GIP and pancreatic hormone. Preliminary studies suggest it could assist patients lose up to 25% of their body weight. Nicknamed the “triple G”, the substance is being hailed digitally as the next Ozempic.

Medical Professionals Express Concerns

Nevertheless, doctors and pharmacists have cautions that the distribution of what remains an unlicensed drug in the United Kingdom is a cause for concern and could result in users administering substances of unknown origin.

Several experts stated the popularity for retatrutide could be linked to the increasing price of licensed weight loss products such as Mounjaro.

Regulatory Status and Enforcement

Marketing the unapproved drug on social media or Telegram is prohibited in the UK, as it is an unapproved medication that cannot be marketed or supplied for personal consumption under the British medical regulations.

Several influencers attempt to circumvent the regulations by calling to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a controlled substance, but advertising and supply can still violate pharmaceutical, marketing, and consumer regulations, potentially leading to fines, legal action or imprisonment.

Service Response and Content Elimination

According to TikTok, the platform has removed violative material and banned associated hashtags and query recommendations. The company stated it was dedicated to maintaining the platform secure and allocating resources in strengthening compliance measures.

Digital Trading Activities

Research also discovered communities with up to 9,000 members marketing the experimental drug using the platform's built-in discovery tool, which operates like a public directory. Entering “retatrutide” immediately displays channels with thousands of members, filled with images of slimming results, positive testimonials and step-by-step instructions for mixing or administering at residence.

After moments of entering one group, a vendor shared contact information, where most transactions occur. The vendor sent an instruction manual and promised shipping within two days. When asked whether the product was authentic, one seller responded: “You can’t be sure.” Another provided a image of a supposed testing documentation. None inquired about weight, medical conditions or past usage.

Item Information and Costs

Inside these groups, posts display black plastic parcels with Royal Mail stickers, claiming to include fresh supplies. One communication stated: “It took eight of us to load them this morning.”

Customers can choose between powder vials, prepared at residence with purified liquid, or ready-to-use pens typically priced at 160 pounds for 20 milligrams. When questioned how long a injector should be used, vendors give conflicting responses varying between a several days to “depends on your body”.

Platform Moderation and Security Actions

A spokesperson for Telegram stated it actively moderated harmful content on its service including content that promoted the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.

Healthcare Professional Cautions

“People are administering materials they cannot confirm. Although the science behind this drug is valid, these online products may not contain what they advertise,” said a pharmacy expert, the director of pharmacy at a pharmacy service.

A medical professional of Asda Online Doctor linked the surge in interest to current cost increases for approved weight-loss medications such as Mounjaro. “With costs rising, individuals are turning to social media. But counterfeit treatments are extremely risky. You can’t be certain what’s inside or whether the environment they were made in was clean,” she said.

Her staff has previously encountered patients injured by personal administration from unconfirmed suppliers. “We recognize the frustration, but purchasing from Telegram or WhatsApp is taking chances with your well-being,” stated the doctor. “These materials could be impure or improperly measured.”

Producer Statement

A spokesperson from Eli Lilly said retatrutide was in third stage research studies and had not been evaluated or authorized by any regulatory agency anywhere in the world. “Therefore at this point no one can sell [it] for personal consumption,” they said, adding that any product “misleadingly claiming itself as a company investigational substance not yet approved … may subject users to potentially serious health risks”.